← All trials
NCT04874870
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2021
- Primary completion
- Jun 1, 2023
- Completion date
- Jun 1, 2023
- First posted
- May 6, 2021
- Last posted
- Aug 20, 2021
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Foundation for Orthopaedic Research and EducationLead sponsor
- Florida Orthopaedic InstituteOverall official - principal investigator
- Foundation for Orthopaedic Research and EducationReponsible party - principal investigator
- Endo PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.